Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KALA KALA BIO	$7.50 +10.8%	$5.17	$2.92 ▼ $11.20	$43.68M	-1.81	216,393 shs	138,258 shs
KPTI Karyopharm Therapeutics	$3.93 +3.1%	$4.38	$3.51 ▼ $16.95	$32.92M	0.28	225,958 shs	64,132 shs
MAAQ Mana Capital Acquisition	$3.88 -6.3%	$4.11	$5.35 ▼ $10.25	$48.67M	N/A	33,075 shs	44,398 shs
TRAW Traws Pharma	$1.46 -5.2%	$1.56	$0.97 ▼ $19.44	$8.57M	1.14	70,741 shs	64,288 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KALA KALA BIO	+10.78%	-7.29%	+48.51%	+100.00%	+13.98%
KPTI Karyopharm Therapeutics	+3.15%	-9.66%	-14.75%	-46.60%	-73.50%
MAAQ Mana Capital Acquisition	0.00%	-4.21%	+21.53%	+926.51%	+893.95%
TRAW Traws Pharma	-5.19%	-7.59%	0.00%	+2.82%	+145,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
KALA KALA BIO	3.7035 of 5 stars	3.5	2.0	0.0	4.4	1.5	0.8	0.6
KPTI Karyopharm Therapeutics	3.4275 of 5 stars	3.4	0.0	0.0	4.6	0.6	2.5	0.6
MAAQ Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TRAW Traws Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KALA KALA BIO	3.00	Buy	$13.00	73.33% Upside
KPTI Karyopharm Therapeutics	2.80	Moderate Buy	$37.40	851.65% Upside
MAAQ Mana Capital Acquisition	0.00	N/A	N/A	N/A
TRAW Traws Pharma	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest TRAW, KALA, MAAQ, and KPTI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/11/2025	KALA KALA BIO	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
7/11/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$27.00
6/2/2025	KALA KALA BIO	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$15.00
5/23/2025	KALA KALA BIO	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $12.00
5/13/2025	KPTI Karyopharm Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$34.00 ➝ $33.00
5/13/2025	KPTI Karyopharm Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$5.00 ➝ $10.00
5/13/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$54.00 ➝ $42.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KALA KALA BIO	$3.89M	12.44	N/A	N/A	$2.02 per share	3.71
KPTI Karyopharm Therapeutics	$145.24M	0.23	N/A	N/A	($22.10) per share	-0.18
MAAQ Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A
TRAW Traws Pharma	$230K	35.29	N/A	N/A	($8.66) per share	-0.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KALA KALA BIO	-$38.51M	-$8.24	N/A	N/A	N/A	N/A	-369.29%	-64.99%	8/5/2025 (Estimated)
KPTI Karyopharm Therapeutics	-$76.42M	-$13.26	N/A	N/A	N/A	-43.99%	N/A	-35.95%	8/5/2025 (Estimated)
MAAQ Mana Capital Acquisition	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
TRAW Traws Pharma	-$166.52M	-$32.81	N/A	N/A	N/A	-15,245.81%	N/A	-193.21%	8/21/2025 (Estimated)

Latest TRAW, KALA, MAAQ, and KPTI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	KALA KALA BIO	-$1.82	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	KPTI Karyopharm Therapeutics	-$3.72	N/A	N/A	N/A	$37.92 million	N/A
5/15/2025	Q1 2025	TRAW Traws Pharma	-$8.04	$2.09	+$10.13	$2.09	$0.06 million	$0.06 million
5/12/2025	Q1 2025	KPTI Karyopharm Therapeutics	-$4.21	-$2.77	+$1.44	-$2.77	$35.12 million	$30.02 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
KALA KALA BIO	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A
MAAQ Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A
TRAW Traws Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KALA KALA BIO	3.19	1.99	1.99
KPTI Karyopharm Therapeutics	N/A	1.33	1.28
MAAQ Mana Capital Acquisition	N/A	N/A	N/A
TRAW Traws Pharma	N/A	1.81	1.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KALA KALA BIO	24.61%
KPTI Karyopharm Therapeutics	66.44%
MAAQ Mana Capital Acquisition	68.44%
TRAW Traws Pharma	7.95%

Insider Ownership

Company	Insider Ownership
KALA KALA BIO	8.32%
KPTI Karyopharm Therapeutics	2.98%
MAAQ Mana Capital Acquisition	N/A
TRAW Traws Pharma	13.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KALA KALA BIO	30	6.45 million	5.92 million	Not Optionable
KPTI Karyopharm Therapeutics	380	8.64 million	8.38 million	Optionable
MAAQ Mana Capital Acquisition	1	8.13 million	N/A	Not Optionable
TRAW Traws Pharma	17	5.56 million	4.81 million	Optionable

TRAW, KALA, MAAQ, and KPTI Headlines

Recent News About These Companies

TRAW - Traws Pharma Inc Sustainability - Morningstar

July 16, 2025 | morningstar.comM

Cooling US Bird Flu Wave Removes Tailwind For Moderna, Novavax, CureVac, Traws Pharma

July 8, 2025 | msn.com

Traws Pharma announces chief financial officer transition

July 5, 2025 | uk.investing.com

Traws Pharma, Inc. (TRAW) Income Statement - Yahoo Finance

July 2, 2025 | finance.yahoo.com

Traws Pharma, Inc.: Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions

June 30, 2025 | finanznachrichten.de

Traws Pharma Submits Phase 2 Protocols for Tivoxavir Marboxil and Ratutrelvir to HREC and FDA

June 30, 2025 | quiverquant.comQ

Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions

June 30, 2025 | globenewswire.com

Traws Pharma Announces Promising Clinical Data for Rigosertib in Rare Cancer

June 5, 2025 | msn.com

Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib

June 3, 2025 | globenewswire.com

Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness

May 27, 2025 | globenewswire.com

Traws Pharma Unveils New Strategic Antiviral Focus

May 19, 2025 | tipranks.com

Traws Pharma Highlights Q1 2025 Financial Progress and Antiviral Developments

May 18, 2025 | msn.com

Traws Pharma Reports First Quarter 2025 Results and Business Highlights

May 15, 2025 | globenewswire.com

Traws Pharma Appoints New Chairman Amid Leadership Changes

April 18, 2025 | tipranks.com

The Escalator: HHS, Spectrum Science, Alvotech and more

April 3, 2025 | mmm-online.comM

Traws Pharma Reports 2024 Financial Results and Advances Bird Flu and COVID Programs

April 2, 2025 | msn.com

Traws Pharma reports FY24 EPS ($35.21)

April 1, 2025 | markets.businessinsider.com

Traws Pharma, Inc. (TRAW) Virtual Investor Event Transcript

April 1, 2025 | seekingalpha.com

Traws Pharma, Inc.: Traws Pharma Reports Full Year 2024 Results and Business Highlights

March 31, 2025 | finanznachrichten.de

Traws Pharma Reports Full Year 2024 Results and Business Highlights

March 31, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRAW, KALA, MAAQ, and KPTI Company Descriptions

KALA BIO NASDAQ:KALA

$7.50 +0.73 (+10.78%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$7.60 +0.09 (+1.27%)

As of 08/1/2025 07:58 PM Eastern

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Karyopharm Therapeutics NASDAQ:KPTI

$3.93 +0.12 (+3.15%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$3.94 +0.01 (+0.25%)

As of 08/1/2025 04:10 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Mana Capital Acquisition NASDAQ:MAAQ

$3.88 -0.26 (-6.28%)

As of 08/1/2025

Mana Capital Acquisition Corp. focuses on engaging in a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to focus on businesses operating in the healthcare, technology, green economy, and consumer products sectors in North America, Europe, and Asia. The company was incorporated in 2021 and is based in Dover, Delaware.

Traws Pharma NASDAQ:TRAW

$1.46 -0.08 (-5.19%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$1.50 +0.04 (+2.67%)

As of 08/1/2025 07:53 PM Eastern

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time